ClinicalTrials.gg
CompletedNCT06122194Updated Jan 30, 2025Results posted

A Study to Learn PF-07817883 Blood Levels After Administration of Tablets of Study Drug to Healthy Adult Volunteers

A Phase 1 interventional study of Drug: PF-07817883 in Healthy, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-30.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to estimate the oral bioavailability of 3 new formulations of PF-07817883 (test) relative to reference tablet formulation in healthy adult participants under fasted conditions. The study will also assess the safety and tolerability of test and reference tablet formulations in healthy adult participants.

Read the detailed description

This is a Phase 1, open-label, randomized, 4-period, 4-sequence crossover study in healthy adult participants evaluating the rBA of 3 new PF-07817883 test oral formulation(s) compared to PF-07817883 reference oral formulation. Approximately 12 participants will be enrolled in this study with approximately equal number of participants randomized to 1 of 4 sequences.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants aged 18 years or older, at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and standard 12-lead .
  • of 16 to 32 kg/m2; and a total body weight >45 kg
  • Capable of giving signed .

Exclusion criteria

Exclusion Criteria:

  • Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior, laboratory abnormality, or other conditions and situations that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).

    1. Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
    2. History of infection, , or ; positive testing for HIV, HBsAg, or HCVAb. Hepatitis B vaccination is allowed.
  • Positive test result for SARS-CoV-2 infection at admission
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Period 1 formulation 1 PF-07817883

    Single oral dose of PF-07817883 tablet under fasted condition

    Drug: Drug: PF-07817883

  • Experimental
    Period 2 formulation 2 PF-07817883

    Single oral dose of PF-07817883 tablet under fasted condition

    Drug: Drug: PF-07817883

  • Experimental
    Period 3 formulation 3 PF-07817883

    Single oral dose of PF-07817883 tablet under fasted condition

    Drug: Drug: PF-07817883

  • Experimental
    Period 4 formulation 4 PF-07817883

    Single oral dose of PF-07817883 tablet under fasted condition

    Drug: Drug: PF-07817883

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of PF-07817883

    Time frame: 0, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post-dose on Day 1 of each treatment period

  2. Area Under the Concentration-time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of PF-07817883

    Time frame: 0, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post-dose on Day 1 of each treatment period

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. Treatment-emergent are events between first dose of study treatment and up to 28-35 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: From start of study treatment (Day 1) up to 28-35 days after last dose of study treatment (maximum up to 47 days)

  2. Number of Participants With Laboratory Test Abnormalities

    Laboratory parameters included hematology (eosinophils/leukocytes \[%\] greater than \[\>\] 1.2\*upper limit of normal), and urinalysis (urine hemoglobin and leukocyte esterase greater than or equal \[\>=\] to 1).

    Time frame: From start of study treatment (Day 1) up to last dose of study treatment (maximum up to 12 days)

  3. Number of Participants With Clinically Significant Abnormality in Vital Signs

    Vital signs included diastolic blood pressure (DBP), systolic blood pressure (SBP) and pulse rate (PR) were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value less than (\<) 90 millimeters of mercury (mmHg), change from baseline greater than or equal to (\>=) 30 mmHg increase, change from baseline \>=30 mmHg decrease; DBP: value \<50 mmHg, change from baseline \>=20 mmHg increase, change from baseline \>=20 mmHg decrease; PR: value \<40 beats per minute (bpm), value greater than (\>) 120 bpm.

    Time frame: From start of study treatment (Day 1) up to last dose of study treatment (maximum up to 12 days)

  4. Number of Participants With Clinically Significant Abnormality in Electrocardiogram (ECG)

    Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest. Criteria were PR interval (\>=300 millisecond \[msec\], percent \[%\] change from baseline \>=25 to 50%), QRS duration (\>=140 msec, %change from baseline \>=50%), corrected QT interval using Fridericia's formula (QTcF) (\>500 msec, %change from baseline \>60 msec, 450 msec\<value less than equal to \[\<=\] 480 msec, 480 msec\<value\<=500 msec, 30 msec\<=change\<=60 msec).

    Time frame: From start of study treatment (Day 1) up to last dose of study treatment (maximum up to 12 days)

07

Results

Posted Jan 30, 2025

Participant flow

A total of 12 participants were enrolled and randomized in this study to 1 of the 4 study treatment sequences.

Treatment Period 1 (3 Days)
Participant flow — Treatment Period 1 (3 Days)
MilestoneTreatment Sequence 1: A Then B Then C Then DTreatment Sequence 2: B Then D Then A Then CTreatment Sequence 3: C Then A Then D Then BTreatment Sequence 4: D Then C Then B Then A
Started3333
Treated3333
Completed3323
Not completed0010
Withdrew: Adverse event0010
Treatment Period 2 (3 Days)
Participant flow — Treatment Period 2 (3 Days)
MilestoneTreatment Sequence 1: A Then B Then C Then DTreatment Sequence 2: B Then D Then A Then CTreatment Sequence 3: C Then A Then D Then BTreatment Sequence 4: D Then C Then B Then A
Started3323
Completed3323
Not completed0000
Treatment Period 3 (3 Days)
Participant flow — Treatment Period 3 (3 Days)
MilestoneTreatment Sequence 1: A Then B Then C Then DTreatment Sequence 2: B Then D Then A Then CTreatment Sequence 3: C Then A Then D Then BTreatment Sequence 4: D Then C Then B Then A
Started3323
Completed3323
Not completed0000
Treatment Period 4 (3 Days)
Participant flow — Treatment Period 4 (3 Days)
MilestoneTreatment Sequence 1: A Then B Then C Then DTreatment Sequence 2: B Then D Then A Then CTreatment Sequence 3: C Then A Then D Then BTreatment Sequence 4: D Then C Then B Then A
Started3323
Completed3323
Not completed0000

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) of PF-07817883
Time frame:
0, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post-dose on Day 1 of each treatment period
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of PF-07817883
nanogram per milliliter (ng/mL)Treatment A: PF-07817883 300 mg Reference FormulationTreatment B: PF-07817883 300 mg Test Formulation 1Treatment C: PF-07817883 300 mg Test Formulation 2Treatment D: PF-07817883 300 mg Test Formulation 3
Maximum Observed Plasma Concentration (Cmax) of PF-078178832308 ± 392579 ± 284266 ± 403566 ± 34
Statistical analysis
  • Treatment A: PF-07817883 300 mg Reference Formulation vs Treatment B: PF-07817883 300 mg Test Formulation 1 · Ratio of adjusted geometric means: 112.15 · 90% CI 93.01 to 135.22
  • Treatment A: PF-07817883 300 mg Reference Formulation vs Treatment C: PF-07817883 300 mg Test Formulation 2 · Ratio of adjusted geometric means: 187.37 · 90% CI 155.79 to 225.35
  • Treatment A: PF-07817883 300 mg Reference Formulation vs Treatment D: PF-07817883 300 mg Test Formulation 3 · Ratio of adjusted geometric means: 153.61 · 90% CI 127.40 to 185.21
PrimaryArea Under the Concentration-time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of PF-07817883
Time frame:
0, 0.5, 1, 2, 4, 6, 8, 12, 24, 48 hours post-dose on Day 1 of each treatment period
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Area Under the Concentration-time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of PF-07817883
nanogram*hour per milliliter (ng*hr/mL)Treatment A: PF-07817883 300 mg Reference FormulationTreatment B: PF-07817883 300 mg Test Formulation 1Treatment C: PF-07817883 300 mg Test Formulation 2Treatment D: PF-07817883 300 mg Test Formulation 3
Area Under the Concentration-time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of PF-0781788317660 ± 3518200 ± 2221040 ± 3621510 ± 33
Statistical analysis
  • Treatment A: PF-07817883 300 mg Reference Formulation vs Treatment B: PF-07817883 300 mg Test Formulation 1 · Ratio of adjusted geometric means: 102.59 · 90% CI 91.09 to 115.54
  • Treatment A: PF-07817883 300 mg Reference Formulation vs Treatment C: PF-07817883 300 mg Test Formulation 2 · Ratio of adjusted geometric means: 125.07 · 90% CI 110.81 to 141.17
  • Treatment A: PF-07817883 300 mg Reference Formulation vs Treatment D: PF-07817883 300 mg Test Formulation 3 · Ratio of adjusted geometric means: 121.75 · 90% CI 108.65 to 136.43
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. Treatment-emergent are events between first dose of study treatment and up to 28-35 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
From start of study treatment (Day 1) up to 28-35 days after last dose of study treatment (maximum up to 47 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsTreatment A: PF-07817883 300 mg Reference FormulationTreatment B: PF-07817883 300 mg Test Formulation 1Treatment C: PF-07817883 300 mg Test Formulation 2Treatment D: PF-07817883 300 mg Test Formulation 3
Number of Participants With Treatment-emergent Adverse Events (TEAEs)2232
SecondaryNumber of Participants With Laboratory Test Abnormalities

Laboratory parameters included hematology (eosinophils/leukocytes \[%\] greater than \[\>\] 1.2\*upper limit of normal), and urinalysis (urine hemoglobin and leukocyte esterase greater than or equal \[\>=\] to 1).

Time frame:
From start of study treatment (Day 1) up to last dose of study treatment (maximum up to 12 days)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities
ParticipantsTreatment A: PF-07817883 300 mg Reference FormulationTreatment B: PF-07817883 300 mg Test Formulation 1Treatment C: PF-07817883 300 mg Test Formulation 2Treatment D: PF-07817883 300 mg Test Formulation 3
Number of Participants With Laboratory Test Abnormalities1012
SecondaryNumber of Participants With Clinically Significant Abnormality in Vital Signs

Vital signs included diastolic blood pressure (DBP), systolic blood pressure (SBP) and pulse rate (PR) were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value less than (\<) 90 millimeters of mercury (mmHg), change from baseline greater than or equal to (\>=) 30 mmHg increase, change from baseline \>=30 mmHg decrease; DBP: value \<50 mmHg, change from baseline \>=20 mmHg increase, change from baseline \>=20 mmHg decrease; PR: value \<40 beats per minute (bpm), value greater than (\>) 120 bpm.

Time frame:
From start of study treatment (Day 1) up to last dose of study treatment (maximum up to 12 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormality in Vital Signs
ParticipantsTreatment A: PF-07817883 300 mg Reference FormulationTreatment B: PF-07817883 300 mg Test Formulation 1Treatment C: PF-07817883 300 mg Test Formulation 2Treatment D: PF-07817883 300 mg Test Formulation 3
Number of Participants With Clinically Significant Abnormality in Vital Signs0000
SecondaryNumber of Participants With Clinically Significant Abnormality in Electrocardiogram (ECG)

Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest. Criteria were PR interval (\>=300 millisecond \[msec\], percent \[%\] change from baseline \>=25 to 50%), QRS duration (\>=140 msec, %change from baseline \>=50%), corrected QT interval using Fridericia's formula (QTcF) (\>500 msec, %change from baseline \>60 msec, 450 msec\<value less than equal to \[\<=\] 480 msec, 480 msec\<value\<=500 msec, 30 msec\<=change\<=60 msec).

Time frame:
From start of study treatment (Day 1) up to last dose of study treatment (maximum up to 12 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormality in Electrocardiogram (ECG)
ParticipantsTreatment A: PF-07817883 300 mg Reference FormulationTreatment B: PF-07817883 300 mg Test Formulation 1Treatment C: PF-07817883 300 mg Test Formulation 2Treatment D: PF-07817883 300 mg Test Formulation 3
Number of Participants With Clinically Significant Abnormality in Electrocardiogram (ECG)0000

Adverse events

Collected over From start of study treatment (Day 1) up to 28-35 days after last dose of study treatment (maximum up to 47 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A: PF-07817883 300 mg Reference Formulation0/11 (0%)0/11 (0%)2/11 (18.2%)
Treatment B: PF-07817883 300 mg Test Formulation 10/11 (0%)0/11 (0%)2/11 (18.2%)
Treatment C: PF-07817883 300 mg Test Formulation 20/12 (0%)0/12 (0%)3/12 (25%)
Treatment D: PF-07817883 300 mg Test Formulation 30/11 (0%)0/11 (0%)2/11 (18.2%)
Most frequent other events
Most frequent other events
EventTreatment A: PF-07817883 300 mg Reference FormulationTreatment B: PF-07817883 300 mg Test Formulation 1Treatment C: PF-07817883 300 mg Test Formulation 2Treatment D: PF-07817883 300 mg Test Formulation 3
Lip dryGastrointestinal disorders0/111/110/120/11
Vessel puncture site bruiseGeneral disorders1/110/110/120/11
Pain in extremityMusculoskeletal and connective tissue disorders0/111/110/120/11
HeadacheNervous system disorders1/110/111/121/11
HaematomaVascular disorders0/110/110/121/11
LymphadenopathyBlood and lymphatic system disorders0/110/111/120/11
NauseaGastrointestinal disorders0/110/111/120/11
InfluenzaInfections and infestations0/110/111/120/11
PolyuriaRenal and urinary disorders0/110/111/120/11
HypertensionVascular disorders0/110/111/120/11

Baseline characteristics

Safety analysis set included all participants randomly assigned to study treatment and who took at least 1 dose of study treatment in at least one treatment period. Participants were analyzed according to the product they actually received.

Age, Continuous
Age, Continuous(Years)Treatment Sequence 1: A Then B Then C Then DTreatment Sequence 2: B Then D Then A Then CTreatment Sequence 3: C Then A Then D Then BTreatment Sequence 4: D Then C Then B Then ATotal
Mean (SD)58.7 ± 4.9334.7 ± 3.0641.3 ± 18.1551.0 ± 21.2846.4 ± 15.48
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Sequence 1: A Then B Then C Then DTreatment Sequence 2: B Then D Then A Then CTreatment Sequence 3: C Then A Then D Then BTreatment Sequence 4: D Then C Then B Then ATotal
Female11013
Male22329
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Sequence 1: A Then B Then C Then DTreatment Sequence 2: B Then D Then A Then CTreatment Sequence 3: C Then A Then D Then BTreatment Sequence 4: D Then C Then B Then ATotal
Hispanic or Latino00101
Not Hispanic or Latino332311
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Sequence 1: A Then B Then C Then DTreatment Sequence 2: B Then D Then A Then CTreatment Sequence 3: C Then A Then D Then BTreatment Sequence 4: D Then C Then B Then ATotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White333312
More than one race00000
Unknown or Not Reported00000
08

Study locations

1 site
  • Pfizer Clinical Research Unit - Brussels
    Brussels, Bruxelles-capitale, Région DE B-1070, Belgium
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Jan 2024, 1 month.

Results were first posted in Jan 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2023
First posted
Nov 8, 2023
StartActual
Nov 23, 2023
Primary completionActual
Jan 12, 2024
CompletionActual
Jan 12, 2024
Results first posted
Jan 30, 2025
Last update
Jan 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06122194
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 8, 2023
Start date
Nov 23, 2023
Primary completion
Jan 12, 2024
Completion
Jan 12, 2024
Results posted
Jan 30, 2025
Last update
Jan 30, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuzatrelvir

Start the discussion